The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2019 | Crossing the PACIFIC: will immunotherapy cure lung cancer?
Martin Reck, MD, PhD, of Hospital Grosshansdorf, Grosshansdorf, Germany, discusses the PACIFIC and beyond from the British Thoracic Oncology Group (BTOG) 2019 Annual Conference in Dublin, Ireland. The results of the PACIFIC trial (NCT02125461) of durvalumab consolidation therapy for locally-advanced non-small cell lung cancer (NSCLC) are practice-changing, showing for the first time the efficacy of a consolidation therapy in this setting. Prof. Reck now highlights considerations for patient selection for this therapy in terms of PD-L1 expression.
